We are committed to improve cannabis genetics in the long-term for a positive future of this industry, innovating and developing what customers need and want.
Puregene combines extensive cannabis experience with state-of-the-art research, driving new variety and cannabinoid development.
Product groups
Puregene provides fast-track development of varieties and traits to cannabis and hemp breeders and producers of all industries.
Trait Licensing
By “trait licensing” our clients gain access to our trait portfolio and have the possibility to license Puregene's protected traits, which includes licenses to our IP rights such as minor cannabinoid traits.
Learn more about our trait licensing:
Tailor-made Varieties
Puregenes "Tailor-made varieties" lets breeders and producers of all industries design the exact plant they want with the individual traits they need. Our technology enables us to perform single trait introgressions into a variety, all the way to building a new stable variety from start to finish.
Learn more about our tailor-made varieties offer:
Varieties
Our Varieties collection lets industry participants choose their favorite variety from our “Elite Variety” catalogue. These can then be cultivated or multiplied via clones or seeds. The chosen variety can then be sold under a respective brand.
Learn more about our varieties:
Latest Stories
Welcome Cannabis! You are becoming a remedy.
The National Council has amended the law, facilitating the medical use of cannabis.
«This experiment will accelerate our breeding program far beyond anything else in the world»
Dr. Gavin George is the Lead Technology Manager at Puregene AG. We took the chance ...
«It is going to be a new playground for our ambitious team»
Dr. Michael Ruckle, director of plant sciences at Puregene AG, is taking us to the ...
Puregene’s Data Driven Trait Discovery
Introducing Puregene's data collection process for high-throughput phenotyping on our field with more than 20'000 ...
Interview mit Stevens Senn zur potenziellen Einstufung von CBD als Betäubungsmittel
Bei einer Neu-Einstufung von CBD als Betäubungsmittel seitens EU, werden die Konsumenten die Verlierer sein
“Our guests reaction shows – We should share our knowledge”
Yannik Schlup, Chief Scientific Officer at Puregene AG, welcomes the invited guests to the first ...